Form 4: Akero Therapeutics Executive Catriona Yale Reports Stock Acquisition

Catriona Yale, Chief Development Officer of Akero Therapeutics, reports acquiring 1,064 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• Catriona Yale, the Chief Development Officer of Akero Therapeutics, Inc., filed a Form 4 on July 2, 2024, reporting a change in beneficial ownership.
• On June 28, 2024, Ms. Yale acquired 1,064 shares of Akero Therapeutics common stock through the company's 2019 Employee Stock Purchase Plan.
• The shares were purchased at a price of $19.941 per share, representing 85% of the closing price of Akero Therapeutics' common stock on that date.
• Following the transaction, Ms. Yale directly owns 75,931 shares of Akero Therapeutics common stock.

Sentiment

Score: 6

Explanation: Routine insider transaction; slightly positive due to insider confidence but not significantly impactful.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Executive stock purchases are common and are often viewed as a sign of confidence in the company's future. The Employee Stock Purchase Plan is a common benefit offered by companies to incentivize employee ownership.

Related Party Transactions

• The stock purchase via the Employee Stock Purchase Plan is a related party transaction.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders as it is a routine purchase under the company's employee stock purchase plan.

Key Dates